WHAT WE DO
Akribion Genomics develops groundbreaking CRISPR nucleases into a new class of genetics-based cancer therapies and advanced genome editing tools.
Powered by BRAIN Biotech Group BioIncubator
LEARN MORE ABOUT OUR TECHNOLOGY
Our Technology Advantage
Get an insight into our innovative technologies and learn more about our novel CRISPR nucleases. Discover the potential of our technology and find the right solution for you.
WHERE TO APPLY OUR TECHNOLOGY
We provide superior solutions for applications in health and biotech
Our genome editing technologies are a core enabler for many markets.
HOW TO ACCESS OUR TECHNOLOGY
EAGER TO INVEST?
Why invest in Akribion?
Are you interested to become part of our journey? Here are six reasons why you should invest in Akribion Genomics.
READ THE NEWS
An alternative CRISPR-Cas nuclease for biotech & pharma Specialty Chemicals has published…
Read moreAkribion Genomics receives the Hessian Founder Award for its innovative approach to…
Read moreBRAIN Biotech AG’s Akribion Genomics technology receives patent approval for its groundbreaking…
Read moreBRAIN Biotech AG Scientist receives VAAM Innovation Award for the discovery of…
Read moreAkribion Genomics successfully competes in Science4Life Venture Cup competition
Read moreBRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology…
Read moreBRAIN Group’s Akribion Genomics business will prioritize the development of therapeutic applications…
Read moreMEET THE TEAM
That’s us
The Akribion team is a dynamic mix of highly experienced scientists and leaders with a passion for genome editing. We are constantly looking for great minds to join our team, so have a look at our job opportunities.
GET IN TOUCH
Ready to collaborate?
Get in touch!
* required field